Disease-associated marked hyperalphalipoproteinemia

Ken-Ichi Hirano; Hironori Nagasaka; Kazuhiro Kobayashi; Satoshi Yamaguchi; Akira Suzuki; Tatsushi Toda; Manabu Doyu

doi:10.1016/j.ymgmr.2014.06.001

Disease-associated marked hyperalphalipoproteinemia

Mol Genet Metab Rep. 2014 Jun 30:1:264-268. doi: 10.1016/j.ymgmr.2014.06.001. eCollection 2014.

Authors

Ken-Ichi Hirano¹, Hironori Nagasaka², Kazuhiro Kobayashi³, Satoshi Yamaguchi¹, Akira Suzuki¹, Tatsushi Toda³, Manabu Doyu⁴

Affiliations

¹ Laboratory of Cardiovascular Disease, Novel, Non-invasive, and Nutritional Therapeutics (CNT), Graduate School of Medicine, Osaka University, Osaka 565-0874, Japan.
² Department of Pediatrics, Takarazuka City Hospital, Takarazuka, Hyogo 665-0827, Japan.
³ Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
⁴ Department of Neurology, Aichi Medical University, Aichi 480-1195, Japan.

Abstract

Marked hyperalphalipoproteinemia (HAL) is a heterogeneous syndrome. To clarify the pathophysiological significance of HAL, we compared clinical profiles between marked HAL subjects with and without cholesteryl ester transfer protein (CETP) deficiency. CETP deficiency was associated with cardiovascular diseases and strokes in the HAL population, particularly in female. HAL women without CETP deficiency tended to have higher prevalence with cancer history. HAL may not always be a longevity marker, but be sometimes accompanied with pathological conditions.

Keywords: Atherosclerosis; Cardiovascular disease; Cholesteryl ester transfer protein deficiency; High density lipoprotein; Hyperalphalipoproteinemia; Stroke.